These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1820045)

  • 1. Enzyme-assisted semisynthesis of shortened B26-modified insulins.
    Sievert D; Gattner HG; Lenz V; Höcker H
    Biomed Biochim Acta; 1991; 50(10-11):S197-200. PubMed ID: 1820045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semisynthetic des-(B27-B30)-insulins with modified B26-tyrosine.
    Lenz V; Gattner HG; Sievert D; Wollmer A; Engels M; Höcker H
    Biol Chem Hoppe Seyler; 1991 Jul; 372(7):495-504. PubMed ID: 1930732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shortened insulin analogues: marked changes in biological activity resulting from replacement of TyrB26 and N-methylation of peptide bonds in the C-terminus of the B-chain.
    Záková L; Barth T; Jirácek J; Barthová J; Zórad S
    Biochemistry; 2004 Mar; 43(8):2323-31. PubMed ID: 14979729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the C-terminus of the insulin B-chain in modulating structural and functional properties of the hormone.
    Leyer S; Gattner HG; Leithäuser M; Brandenburg D; Wollmer A; Höcker H
    Int J Pept Protein Res; 1995 Nov; 46(5):397-407. PubMed ID: 8567184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-function relationships of des-(B26-B30)-insulin.
    Spoden M; Gattner HG; Zahn H; Brandenburg D
    Int J Pept Protein Res; 1995; 46(3-4):221-7. PubMed ID: 8537175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzymatic semisynthesis of porcine despentapeptide (B26-30) insulin using unprotected desoctapeptide (B23-30) insulin as a substrate. Model studies.
    Kubiak T; Cowburn D
    Int J Pept Protein Res; 1986 May; 27(5):514-21. PubMed ID: 3525439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-function relationships of shortened [LeuB25]insulins, semisynthetic analogues of a mutant human insulin.
    Fischer WH; Saunders D; Brandenburg D; Diaconescu C; Wollmer A; Dodson G; De Meyts P; Zahn H
    Biol Chem Hoppe Seyler; 1986 Sep; 367(9):999-1006. PubMed ID: 3539147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. I222 crystal form of despentapeptide (B26-B30) insulin provides new insights into the properties of monomeric insulin.
    Whittingham JL; Youshang Z; Záková L; Dodson EJ; Turkenburg JP; Brange J; Dodson GG
    Acta Crystallogr D Biol Crystallogr; 2006 May; 62(Pt 5):505-11. PubMed ID: 16627943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A shortened insulin with full in vitro potency.
    Fischer WH; Saunders D; Brandenburg D; Wollmer A; Zahn H
    Biol Chem Hoppe Seyler; 1985 May; 366(5):521-5. PubMed ID: 3890892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semisynthesis and biological activity of porcine [LeuB24]insulin and [LeuB25]insulin.
    Tager H; Thomas N; Assoian R; Rubenstein A; Saekow M; Olefsky J; Kaiser ET
    Proc Natl Acad Sci U S A; 1980 Jun; 77(6):3181-5. PubMed ID: 6997872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward the insulin-IGF-I intermediate structures: functional and structural properties of the [TyrB25NMePheB26] insulin mutant.
    Záková L; Brynda J; Au-Alvarez O; Dodson EJ; Dodson GG; Whittingham JL; Brzozowski AM
    Biochemistry; 2004 Dec; 43(51):16293-300. PubMed ID: 15610023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo metabolic activity of des-(B26-B30)-insulin-B25-amide and related analogues in the rat.
    Stümpel F; Hartmann H; Brandenburg D; Creutzfeldt W
    Diabetes Res Clin Pract; 1990 Jul; 9(3):257-64. PubMed ID: 2226126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and characterization of two LysB29 specifically labelled fluorescent derivatives of human insulin.
    Ciencialová A; Záková L; Jirácek J; Barthová J; Barth T
    J Pept Sci; 2004 Jul; 10(7):470-8. PubMed ID: 15298182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The solution structure of a superpotent B-chain-shortened single-replacement insulin analogue.
    Kurapkat G; Siedentop M; Gattner HG; Hagelstein M; Brandenburg D; Grötzinger J; Wollmer A
    Protein Sci; 1999 Mar; 8(3):499-508. PubMed ID: 10091652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A highly potent insulin: des-(B26-B30)-[AspB10,TyrB25-NH2]insulin(human).
    Schwartz GP; Burke GT; Katsoyannis PG
    Proc Natl Acad Sci U S A; 1989 Jan; 86(2):458-61. PubMed ID: 2643113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin analogues with modifications at position B26. Divergence of binding affinity and biological activity.
    Záková L; Kazdová L; Hanclová I; Protivínská E; Sanda M; Budesínský M; Jirácek J
    Biochemistry; 2008 May; 47(21):5858-68. PubMed ID: 18452310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monomeric B27 Lys destripeptide insulin: semisynthesis, characterization and biological activity.
    Ding JG; Cui DF; Zhang YS
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Mar; 35(3):215-8. PubMed ID: 12621544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural studies on des-pentapeptide (B26-30)-insulin. I. The preparation and properties of des-pentapeptide-insulin.
    Sci Sin; 1976; 19(3):351-7. PubMed ID: 788152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [B-chain shortening of matrix-bound insulin by pepsin, I:Preparation and properties of bovine des-pentapeptide(B26-30) insulin (suthor's transl)].
    Gattner HG
    Hoppe Seylers Z Physiol Chem; 1975 Sep; 356(9):1397-404. PubMed ID: 240771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the phenylalanine B25 side chain in directing insulin interaction with its receptor. Steric and conformational effects.
    Nakagawa SH; Tager HS
    J Biol Chem; 1986 Jun; 261(16):7332-41. PubMed ID: 3519607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.